Inactive Instrument

Press Releases Clearmind Medicine Inc. Canadian Securities Exchange

Equities

Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product	01:24pm	AQ
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment	05-07	AQ
Clearmind Applies to Cease Being a Reporting Issuer in Canada	04-30	AQ
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders	04-17	AQ
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders	04-10	AQ
Clearmind Medicine CEO Issues Letter to Shareholders	04-09	AQ
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China	03-19	AQ
Clearmind Medicine : Condensed Interim Consolidated Financial Statements - Form 6-K	03-19	PU
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals	08/03/22	PR
Clearmind Medicine : Appoints Distinguished Addiction Experts Professor Wim van den Brink and Professor Gabriele Fischer to Its Scientific Advisory Board	14/10/21	GL
Clearmind Medicine : to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20	01/10/21	GL

No results for this search